Pulse Biosciences

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pulse Biosciences pivots to cardiac tech, eyes FDA device market

Pulse Biosciences reported financials, highlighted cardiac ablation technology, and pivoted towards an FDA-approved device for cellular repair, showcasing adaptability and strategic focus.
The company faces challenges in transitioning focus areas and managing financial projections but has strengths in innovation, market potential, and strategic autonomy.
Opportunities lie in licensing breakthrough technologies, commercial partnerships, regulatory milestones, and market disruption, positioning Pulse Biosciences for growth and success.
Overall, Pulse Biosciences' strategic shifts, financial prudence, and focus on innovation present a promising outlook for sustainable growth and market expansion.

Pulse Biosciences advances cardiac ablation tech with strong financials

Pulse Biosciences made notable progress in Q1 2023, showcasing financial improvements, key leadership additions, and advancements in developing innovative cardiac ablation technologies.
While facing challenges in clinical validation and regulatory processes, the company's strategic roadmap and focus on nsPFA technology position them well for future growth and success.
With a strong financial position, experienced leadership, and a clear vision for product development, Pulse Biosciences is poised to capitalize on the market opportunities in cardiac ablation.

Pulse Biosciences advances nsPFA technology in cardiac applications, boosts finances

Pulse Biosciences demonstrated strong progress in nsPFA technology for cardiac applications and showcased financial improvements.
While facing questions about study expansions and project exits, the company remains confident in its market position.
Opportunities lie in expanding nsPFA applications, leveraging positive feedback, and exploring strategic partnerships for growth.

Pulse Biosciences advances CellFX technology, reduces costs, eyes growth opportunities

Pulse Biosciences demonstrated strong performance in technology advancement, cost management, and stakeholder engagement, positioning the company for growth.
Despite challenges related to patent concerns, the company's focus on innovation, safety, and partnerships presents opportunities for expansion and market leadership.
With a solid financial position, strategic development goals, and a commitment to excellence, Pulse Biosciences is poised for continued success in the medical technology sector.

Pulse Biosciences advances innovative surgical technology with promising FDA clearances

Pulse Biosciences is optimistic about the future impact of its energy technology on surgery and emphasizes the importance of strong support structures for successful product launches.

Pulse Biosciences excels in Q2, poised for transformative medical advancements

Pulse Biosciences' Q2 2024 performance reflects progress, financial strength, and strategic focus on pivotal clinical trials.
While facing challenges such as increased costs and operational complexities, the company is well-positioned to leverage opportunities in transformative medical technologies.
With a solid financial foundation, strong leadership, and innovative products, Pulse Biosciences is poised for continued growth and market success.
Navigating regulatory hurdles and market competition will be key as the company advances its nano-PFA technology in medical treatments.

Pulse Biosciences reports Q3 loss, strengthens balance sheet for growth

Pulse Biosciences' Q3 2024 earnings call highlighted progress in medical applications, a strengthened balance sheet, and a focus on pivotal clinical studies in 2025.
While facing challenges with increased expenses and net loss, the company's innovative technology and strategic fundraising efforts position it for future growth.
Opportunities lie in advancing clinical studies, expanding product applications, and solidifying its presence in the healthcare market through strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Pulse Biosciences, Inc. (“Pulse” or the “Company”) (NASDAQ: PLSE) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 8, 2022, Pulse announced that the U.S. Food and Drug Administration (“FDA”) concluded there was insufficient clinical evidence to support the Company's 510(k)

The Law Offices of Frank R. Cruz Continues Investigation of Pulse Biosciences, Inc. (PLSE) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pulse Biosciences, Inc. (“Pulse” or the “Company”) (NASDAQ: PLSE). Investors who purchased Pulse shares are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/plse. The investigation concerns whether Pulse and certain of its officers and/or directors have violated federal securities

Bronstein, Gewirtz & Grossman, LLC Notifies Pulse Biosciences, Inc. (PLSE) Investors of Investigation

The stock price of Pulse Biosciences Inc (NASDAQ: PLSE) fell by 34.44% in the most recent trading session. This is why it happened.

Pulse Biosciences (PLSE) Stock: Why The Price Significantly Fell

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pulse Biosciences, Inc. (“Pulse” or the “Company”) (NASDAQ: PLSE) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Pulse investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities l

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Pulse Biosciences, Inc. (PLSE) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Pulse Biosciences, Inc. (“Pulse” or the “Company”) (NASDAQ: PLSE) investors concerning the Company's possible violations of federal securities laws. On February 8, 2022, Pulse announced that the U.S. Food and Drug Administration (“FDA”) concluded there was insufficient clinical evidence to support the Company's 510(k) submission to expand the label for the CellFX System to treat sebaceous hype

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Pulse Biosciences, Inc. (PLSE) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Pulse Biosciences, Inc. (“Pulse” or the “Company”) (NASDAQ: PLSE) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 8, 2022, Pulse announced that the U.S. Food and Drug Administration (“FDA”) concluded there was insufficient clinical evidence to support the Company's 510(k)

The Law Offices of Frank R. Cruz Announces Investigation of Pulse Biosciences, Inc. (PLSE) on Behalf of Investors

Atlanta, Georgia--(Newsfile Corp. - February 8, 2022) -  Holzer & Holzer, LLC is investigating whether Pulse Biosciences, Inc. ("Pulse Biosciences" or the "Company") (NASDAQ: PLSE) complied with federal securities laws. On February 8, 2022, Pulse Biosciences provided an update on the Company's recent 510(k) submission, which added sebaceous hyperplasia as an indication for use to its CellFX System. In the announcement, the Company revealed it had "received an Additional Information ("AI") letter from the FDA ....

SHAREHOLDER ALERT: Investigation of Pulse Biosciences, Inc. (PLSE) Announced by Holzer & Holzer, LLC

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced an update to its recent U.S. Food and Drug Administration (FDA) 510(k) submission to add the specific indication for treatment of sebaceous hyperplasia to expand the CellFX System's current labeling. The Company submitted a 510(k) in December 2021 to add the treatment of sebaceous h

Pulse Biosciences Provides an Update on Recent FDA 510(k) Submission

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Management is scheduled to conduct meetings with investors during the conference on Tuesday, February 15th and Wednesday, February 16th, 2022. About Pulse Biosciences® P

Pulse Biosciences to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced preliminary unaudited fourth quarter 2021 financial and operational results. Recent Highlights: Preliminary unaudited full year 2021 revenue is expected to be in the range of $1.3 million to $1.4 million, including preliminary unaudited fourth quarter 2021 revenue of approximately $

Pulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Pulse Biosciences, Inc (PLSE)'s Technical Outlook is Bright After Key Golden Cross

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the Stephens Annual Investment Conference in Nashville, Tennessee. Management is scheduled to participate in a fireside chat on Thursday, December 2, 2021 at 2:00pm PT / 4:00pm CT. Interested parties may access the live and recorded webcast on the “Investors”

Pulse Biosciences to Participate in the Stephens Annual Investment Conference

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2021 Results - Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the third quarter of 2021. Recent Highlights Achieved third quarter 2021 revenue of $574 thousand, representing 12 Controlled Launch Program participants opting to acquire their CellFX Systems and transition to commercial use Onboarded 68 CellFX System Controll

Pulse Biosciences Reports Third Quarter 2021 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that members of management will present at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021 at 1:40pm PT / 4:40pm ET. Interested parties may access the on-demand webcast at the same time on the “Investors” section of the Company's website at www.pulsebioscie

Pulse Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter of 2021 after market close on Monday, November 15, 2021. Company management will host a corresponding conference call beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-2

Pulse Biosciences Schedules Third Quarter 2021 Financial Results Conference Call for November 15, 2021

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Laureen DeBuono to its Board of Directors. Concurrent to Ms. DeBuono's appointment, Kenneth Clark has resigned from the Board of Directors. “We are delighted and honored to welcome Laureen to the Pulse Biosciences Board,” said Robert Duggan, Chairman of the Pulse

Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the upcoming virtual H.C. Wainwright Global Investment Conference. Management is scheduled to participate and hold one-on-one meetings Tuesday, September 14, 2021. A presentation webcast will be available at the start of the conference on Monday, September 13, 20

Pulse Biosciences to Participate in the H.C. Wainwright Global Investment Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Mitchell E. Levinson to the newly created role of Chief Strategy Officer, effective immediately, in addition to the continuation of his role as a member of the Pulse Biosciences Board of Directors. “As a Board member and medical device industry veteran with a trac

Pulse Biosciences Announces Appointment of Mitchell E. Levinson as Chief Strategy Officer

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q2 2021 Results - Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the second quarter of 2021. Recent Highlights CellFX System Controlled Launch Program participants totaled 49 at the end of the second quarter, including 34 onboarded during the second quarter across the U.S., Europe and Canada, on track to complete program onb

Pulse Biosciences Reports Second Quarter 2021 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the second quarter of 2021 after market close on Monday, August 9, 2021. Company management will host a corresponding conference call beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201

Pulse Biosciences Schedules Second Quarter 2021 Financial Results Conference Call for August 9, 2021

The medical technology company got rid of $41.6 million in debt with a large private sale of stock on Thursday.

Why Pulse Biosciences Stock Moved Higher Thursday

Pulse Biosciences Inc's (NASDAQ: PLSE) Board Chairman, Robert W. Duggan, will purchase 3.04 million common shares at $16.40 per share in a private placement.

Pulse Biosciences Stock Is Trading Higher After Company's Chairman Agrees To Buy Shares Worth $50M

The stock price of Pulse Biosciences Inc (NASDAQ: PLSE) increased by over 48% during intraday trading. This is why it happened.

News for Pulse Biosciences Stock (PLSE)